Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Binod Dhakal, Meera Mohan, Ravi Narra, Katie Palen, Aniko Szabo, Tyce Kearl, Gayathri Ravi, Susan Bal, Bryon D. Johnson, Marcelo Pasquini, Anita D'Souza, Parameswaran N. Hari, Luciano Costa

Blood (2023) 142 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2023-181266

Published: 2023

Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2023-173954

Published: 2023

Journal Articles

Gene Therapy Expressing Platelet-Derived Factor VIII for Correction of Hemophilia Α with a History of Inhibitors

David A. Wilcox, Myriam Armant, Lynn Malec, Qizhen Shi, Bryon D. Johnson, Huiqing Xu, Lily M. Du, Lisa J. Duffy, Frederic D. Bushman, James H. Jerkins, Peiman Hematti, Ruta Brazauskas, Shawn M. Jobe, Parameswaran N. Hari, Mary Eapen

Blood (2023) 142 (Supplement 1): 2249.

https://doi.org/10.1182/blood-2023-172845

Published: 2023

Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2023-180761

Published: 2023

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study

Blood (2023) 142 (Supplement 1): 785.

https://doi.org/10.1182/blood-2023-179153

Published: 2023

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Anita D'Souza, MD, Baldeep Wirk, MD, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Cristina J. Gasparetto, MD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 193.

https://doi.org/10.1182/blood.V124.21.193.193

Published: 2014

Journal Articles

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Jayanthi Vijayakumar, MBBS, Jeffrey Jackson, MD MPH, Kwang W Ahn, PhD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 4771.

https://doi.org/10.1182/blood.V124.21.4771.4771

Published: 2014

Journal Articles

A Statistical Model for Predicting Neutropenic Fever

Ariel Nelson, MD, Dan Eastwood, MS, Tao Wang, PhD, Karen Carlson, MD PhD, Laura C Michaelis, MD, Marcelo C. Pasquini, MD MS, Parameswaran N. Hari, MD, Christopher R. Chitambar, MD, Timothy S. Fenske, MD, Mary Beth Graham, MD, Mehdi Hamadani, MD, Anita D'Souza, MBBS, MD, Ehab Atallah, MD

Blood (2014) 124 (21): 5258.

https://doi.org/10.1182/blood.V124.21.5258.5258

Published: 2014

Journal Articles

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Ahmad Hanif, MD, Parameswaran N. Hari, MD MRCP, MS, Ehab Atallah, MD, Karen-Sue B. Carlson, MD PhD, Marcelo C. Pasquini, MD, Laura C Michaelis, MD

Blood (2014) 124 (21): 1851.

https://doi.org/10.1182/blood.V124.21.1851.1851

Published: 2014

Journal Articles

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Luciano J Costa, MD PhD, Jia-Xing Huang, MS, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 557.

https://doi.org/10.1182/blood.V124.21.557.557

Published: 2014

Journal Articles

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Luciano J Costa, MD PhD, Geoffrey L. Uy, MD, Parameswaran N. Hari, MD MRCP, MS, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Anita D'Souza, MD

Blood (2014) 124 (21): 2447.

https://doi.org/10.1182/blood.V124.21.2447.2447

Published: 2014

Journal Articles

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Parameswaran N. Hari, MD, Kenneth H. Shain, MD PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD MBA, Sandra J. Dixon, MS, Claudia Paba Prada, MD

Blood (2014) 124 (21): 3453.

https://doi.org/10.1182/blood.V124.21.3453.3453

Published: 2014

Journal Articles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Noopur Raje, MD, Parameswaran N. Hari, MD, MRCP, MS, Heather Landau, MD, Paul G. Richardson, MD, Jacalyn Rosenblatt, MD, Nicole Couture, RN, John F. Lyons, PhD, Gillian Langford, PhD, Murray Yule, MD

Blood (2013) 122 (21): 1976.

https://doi.org/10.1182/blood.V122.21.1976.1976

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Noopur Raje, MD, Dan T. Vogl, MD, MSCE, Parameswaran N. Hari, MD, MRCP, MS, Sundar Jagannath, MD, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, M.D., Ph.D., Paul G. Richardson, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 759.

https://doi.org/10.1182/blood.V122.21.759.759

Published: 2013

Journal Articles

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Noopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones, Catherine Wheeler, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4061.

https://doi.org/10.1182/blood.V120.21.4061.4061

Published: 2012

Journal Articles

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Blood (2012) 120 (20): 4256–4262.

https://doi.org/10.1182/blood-2012-06-436725

Published: 2012

Includes: Supplemental data

Journal Articles

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

Blood (2011) 118 (7): 1979–1988.

https://doi.org/10.1182/blood-2011-02-337329

Published: 2011

Journal Articles

Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.

Theresa Hahn, PhD, Philip L. McCarthy, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Hillard M. Lazarus, MD, Ginna G. Laport, MD, Silvia Montoto, MD, Parameswaran N Hari, MD

Blood (2009) 114 (22): 1215.

https://doi.org/10.1182/blood.V114.22.1215.1215

Published: 2009

NARROW

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Gene Therapy Expressing Platelet-Derived Factor VIII for Correction of Hemophilia Α with a History of Inhibitors

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

A Statistical Model for Predicting Neutropenic Fever

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only